Details for Patent: 7,516,741
✉ Email this page to a colleague
Which drugs does patent 7,516,741 protect, and when does it expire?
Patent 7,516,741 protects TOBI PODHALER and is included in one NDA.
Summary for Patent: 7,516,741
| Title: | Aerosolization apparatus with feedback mechanism |
| Abstract: | An aerosolization apparatus comprises a housing defining a chamber having an air inlet and an air outlet, wherein the chamber is sized to receive a capsule containing a pharmaceutical formulation. A puncturing member is moveable within the chamber to contact the capsule and to provide an opening in the capsule, and a feedback mechanism provides an indication, such as a tactile indication, to a user when the puncturing member has been moved to a position where it provides the opening into the capsule. When air flows through the inlet, the pharmaceutical formulation is aerosolized and the aerosolized pharmaceutical formulation is delivered through the outlet. |
| Inventor(s): | Glusker; Mark J. (San Mateo, CA), Wood; Jeff R. (Mountain View, CA), Burr; John D. (Redwood City, CA) |
| Assignee: | Novartis AG ( |
| Application Number: | 10/704,160 |
|
Patent Claim Types: see list of patent claims | Formulation; Dosage form; Delivery; Device; Use; Process; |
More… ↓ |
Drugs Protected by US Patent 7,516,741
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Speciality Lp | TOBI PODHALER | tobramycin | POWDER;INHALATION | 201688-001 | Mar 22, 2013 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
